Navigation Links
LSUHSC research yields promising stroke treatment
Date:1/23/2010

New Orleans, LA For the first time, research led by Youming Lu, PhD, MD, Professor of Neurology and Neuroscience at LSU Health Sciences Center New Orleans School of Medicine, has identified a novel mechanism that may trigger brain damage during stroke and identified a therapeutic approach to block it. The work, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), both of the National Institutes of Health (NIH), as well as the American Heart Association, will be published in the January 22, 2010 issue of the top tier journal, Cell, available online at 12:00 noon ET on January 21, 2010.

The work focuses on particular receptors for the neurotransmitter, glutamate, called NMDA (N-methyl-D-aspartate) receptors, which constitute the major subtype of glutamate receptors. NMDA receptors play a key role in communication among nerve cells in the brain. They perform a number of necessary functions including playing a role in learning and memory, but can also be involved in processes that cause brain cell death. Under normal conditions, signaling through NMDA receptors prevents the deleterious overload of cells with calcium, but during insults like stroke, this process is disabled. Calcium overload triggers multiple intracellular processes which result in irreversible death of brain cells. The research team discovered that an enzyme, DAPK1 (Death-Associated Protein Kinase 1), binds to a portion of the NMDA receptor, and acts as a specific "NMDA receptor cell death signal" during stroke. The researchers wanted to determine whether the process could be circumvented by disrupting the DAPK1-NMDA receptor binding, and they developed a high potency reagent to test. The reagent not only blocked DAPK1, protecting brain cells against stroke insults, but it did so without affecting other physiological functions of NMDA receptors.

To date, all stroke clinical trials targeting glutamate receptors have failed, largely because of their side effects, inefficient delivery through the blood-brain barrier, and/or a limited time window for therapeutic intervention.

"It is conceivable that this study not only provides new insights into the cellular and molecular basis responsible for stroke damage, but also provides a therapeutic target for stroke therapy," says Dr. Youming Lu, who is also a research scientist at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence.

According to the American Heart Association, stroke is the third leading cause of death in the United States and is a leading cause of serious, long-term disability. NIH-supported research suggests that about one in six Americans will experience a stroke at some point after age 65 and stroke is fatal in 10-20% of cases. Louisiana is in the "stroke belt," an eight-state region in the southeastern United States which one recent study found had a more than 40% higher stroke mortality rate than the rest of the nation.

"By determining that the interaction between the NMDA receptor NR2B subunit and DAPK1 kinase serves as a trigger for cell death during stroke, this research points to a new therapeutic approach for the treatment of stroke that may avoid the negative side effects that have plagued the development of stroke therapeutics to date." said Dr. Suzana Petanceska, of the NIA Division of Neuroscience. "Furthermore, the therapeutic significance of these findings may reach beyond stroke to other neurodegenerative diseases of aging."


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related medicine news :

1. LSUHSC dental school to be awarded top national honor
2. LSUHSC inventor awarded patent for new procedure to detect cancer spread
3. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
4. LSUHSC awarded grant to address nursing shortage
5. LSUHSC public health contributes to estimate of HPV-related cancers
6. LSUHSCs Fontham makes history
7. LSUHSCs Dr. Xiao Cheng Wu co-authors annual report to the nation on cancer
8. LSUHSCs England leads development of new testing guidelines for common nerve disorder
9. LSUHSC research may benefit diabetes by increasing understanding of how to control islet cell growth
10. LSUHSC research shows fish oil protects against diseases like Parkinsons
11. LSUHSC dental researcher funded to develop better dental materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology: